Jade Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Jade Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($127.41M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($46.98M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($75.52M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($51.51M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($22.96M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($9.61M) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($113.54M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($35.54M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($81.41M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($53.24M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($23.02M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($8.89M) | Mar 30, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.12M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $31.23M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $64.22M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $38.62M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $14.99M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $7.94M | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($94.69M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($22.61M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($56.78M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($39.12M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($27.40M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($7.86M) | Mar 30, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.0K | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $142.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $195.0K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $181.0K | Mar 29, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $349.78M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $72.80M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $127.42M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $135.30M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $175.36M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $4.72M | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.26M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $119.60M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $17.96M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.56M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $2.95M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $1.77M | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $332.52M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($46.80M) | Mar 6, 2026 |
| FY2025 | Jun 17, 2024 | $1.0K | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $109.46M | Mar 27, 2025 |
| FY2024 | Dec 31, 2022 | $126.74M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $172.42M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | ($13.34M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2019 | ($3.64M) | Mar 30, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($174.39M) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | ($46.98M) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | ($163.42M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($87.90M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($36.39M) | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | ($13.41M) | Mar 30, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.44M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | $69.39M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | $23.49M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $22.40M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $54.20M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | $4.57M | Mar 30, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (14) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 29, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | (14) | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 29, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.32M | Mar 6, 2026 |
| FY2025 | Dec 31, 2024 | 3.67M | Mar 6, 2026 |
| FY2024 | Dec 31, 2023 | 27.76M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 24.72M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 24.41M | Mar 29, 2023 |
| FY2021 | Dec 31, 2020 | 243,076 | Mar 30, 2022 |